Novo Nordisk | NVO - Net Income


Novo Nordisk reported DKK3.26B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
ANI Pharmaceuticals USD 24.71M 4.78M Jun/2026
Aurora Cannabis CAD -71.1M 72.92M Mar/2026
Bausch Health Companies USD 258M 1.68B Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Canopy Growth CAD -157.11M 94.49M Mar/2026
Corcept Therapeutics USD 42.14M 73.9M Jun/2026
Drreddys Laboratories INR 2.21B 9.89B Mar/2026
Eli Lilly USD 7.1B 301M Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Novo Nordisk DKK 20.99B 5.9B Jun/2026
Novo Nordisk DKK 3.26B 45.29B Jun/2026
Pacira USD 4.65M 1.74M Jun/2026
Perrigo USD 74.5M 473.1M Jun/2026
Phibro Animal Health USD 27.46M 932K Dec/2025
Prestige Brands USD 38.54M 15.39M Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Supernus Pharmaceuticals USD -58.37M 56.08M Jun/2026
Zoetis USD 691M 90M Jun/2026